BRAIN and NERVE Shinkei Kenkyu no Shinpo Volume 71, Issue 6 (June 2019)

Eculizumab Treatment for Refractory Generalized Myasthenia Gravis Akiyuki Uzawa 1 , Satoshi Kuwabara 1 1Department of Neurology, Graduate School of Medicine, Chiba University Keyword: 重症筋無力症 , 補体 , 新規治療 , C5 , エクリズマブ , myasthenia gravis , complement , new treatment , eculizumab pp.565-570
Published Date 2019/6/1
  • Abstract
  • Look Inside
  • Reference


Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction mainly caused by anti-nicotinic acetylcholine receptor (AChR) antibodies. Complements are known to play a prominent role in the pathogenesis of MG. Long-term remission may not necessarily be achieved in MG patients with conventional therapies. Recently, complement inhibitor, the humanized monoclonal anti-C5 antibody eculizumab, complement inhibitor, was approved for patients with anti-AChR antibody-positive generalized refractory MG in Japan. In this review, we focus on the role of complements in the pathogenesis of MG and the action mechanism, efficacy, and future prospects of eculizumab.

Copyright © 2019, Igaku-Shoin Ltd. All rights reserved.


BRAIN and NERVE-神経研究の進歩
71巻6号 (2019年6月)
電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院